Frost & Sullivan Independent Equity Research
BioLineRx Ltd.: Continued execution of multiple clinical development programs for the Company’s lead project – BL-8040; Investment by a principal investor reflects confidence in the company’s strategy. Target Price unchanged.
Report type: Quarterly Update
For all past reports click here
Published on: September 6th 2017